Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia

被引：0
|
作者：
Vanover, Kimberly [1 ]
Correll, Christoph [1 ]
Weingart, Michal [1 ]
Saillard, Jelena [1 ]
Hossain, Shawn [1 ]
Glass, Steven [1 ]
Kozauer, Susan [1 ]
Satlin, Andrew [1 ]
Davis, Robert [1 ]
机构：
[1] Intracellular Therapies Inc, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2018年 / 43卷
关键词：
Schizophrenia Novel Treatment; Long-Term Safety; Antipsychotic;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
T184
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [41] ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
    Lieberman, Jeffrey A.
    Davis, Robert E.
    Correll, Christoph U.
    Goff, Donald C.
    Kane, John M.
    Tamminga, Carol A.
    Mates, Sharon
    Vanover, Kimberly E.
    BIOLOGICAL PSYCHIATRY, 2016, 79 (12) : 952 - 961
  • [42] ITI-007, a First-in-Class Investigational New Drug for the Treatment of Schizophrenia: Prospective Secondary Analyses from the Randomized ITI-007-005 Trial
    Vanover, Kimberly
    Mates, Sharon
    Davis, Robert
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S368 - S369
  • [43] ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes (vol 16, pg 601, 2016)
    Davis, R. E.
    Correll, C. U.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (06) : V - V
  • [44] Metabolic syndrome in bipolar depression with lumateperone (iti-007): a post hoc analysis of 2 randomized, placebo-controlled trials
    Correll, Christoph
    Durgam, Suresh
    Kozauer, Susan G.
    Martin, Margaret
    Huo, Jason
    Mates, Sharon
    BIPOLAR DISORDERS, 2022, 24 : 54 - 54
  • [45] UNIQUELY TARGETED MOLECULAR THERAPEUTIC FOR SCHIZOPHRENIA: CHARACTERIZATION OF ITI-007 IN VITRO AND IN VIVO ANIMAL MODELS
    Wennogle, Lawrence P.
    Snyder, Gretchen L.
    Davis, Robert E.
    Vanover, Kimberly
    Hendrick, Joseph
    Li, Peng
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S153 - S153
  • [46] Metabolic Syndrome in Bipolar Depression with Lumateperone (ITI-007): A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials
    Correll, Christoph U.
    Kozauer, Susan G.
    Lands, Micah
    Huo, Jason
    Durgam, Suresh
    CNS SPECTRUMS, 2023, 28 (02) : 247 - 248
  • [47] ITI-007: A Novel Treatment for Sleep Disorders and Dyskinesia in Parkinson's Disease
    Vanover, K. E.
    Davis, R. E.
    Snyder, G. L.
    Hendrick, J. P.
    Fisone, G.
    Fienberg, A. A.
    Wennogle, L. P.
    Mates, S.
    MOVEMENT DISORDERS, 2010, 25 : S664 - S664
  • [48] ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders
    Davis, Robert E.
    Vanover, Kimberly E.
    Mates, Sharon
    ANNALS OF NEUROLOGY, 2014, 76 : S90 - S90
  • [49] Metabolic Profile of Lumateperone (ITI-007) Monotherapy in Bipolar Depression: A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials
    Davis, Robert
    Durgam, Suresh
    Chen, Richard
    Kozauer, Susan
    Mates, Sharon
    Correll, Christoph
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 274 - 274
  • [50] Unique Pharmacology of ITI-007 Confers Efficacy in the Treatment of Schizophrenia at Low Striatal D2 Receptor Occupancy Levels
    Vanover, Kimberly E.
    Davis, Robert E.
    O'Gorman, Cedric
    Saillard, Jelena
    Weingart, Michal
    Mates, Sharon
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 354S - 355S
12345